Skip Navigation Skip to content

Welcome to Shilpa Medicare Ltd. To learn more about our products and services, please write to us

Please keep me informed of products, services and offerings from Shilpa Medicare.

I accept Shilpa Medicare ‘s Privacy Policy.


Biologics - Platforms in Vaccine

Vaccine Antigen Expression Systems

  • E.coli
  • CHO
  • Yeasts
  • Other Mammalian Cells - HEK-293

Virus Replication Platforms (HOSTS)

  • HEK-293
  • CHO
  • Sf9/Sf21 – Starting up

Viruses And Vectors

  • Adenovirus
  • Adeno-associated virus (AAV)

Potential to collaborate in Co-development mode with shared commercial rights or in CDMO mode based on the disease areas.

Willing to work with and optimise Cell therapies processes based on initial protocols developed at Client site

Our long term strengths

Technical strength

Backward integration – Clone Development to Manufacturing

  • Own cell lines, vectors, process development strengths
  • Complete inhouse characterisation of biologics with high end, high throughput analytical instrumentation
  • Own Cell banking, cell line characterisation facility upcoming
  • Experienced R&D, Scaleup and Manufacturing / Regulatory / Quality team

Infrastructural advantage

Flexible manufacturing - Future proof facility design that incorporates growing trends in continuous processing. Infrastructure for further expansion (8x) available in the existing facility

  • Environment friendly - Low Carbon footprint facility, eliminated dependence on fossil fuels from Sept 2020
  • Multi-product manufacturing unit - enabling multiple product production in single facility